Company intelligence / Profile preview

Neurocarrus

Lincoln, Nebraska, United Statesneurocarrus.com ↗

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

Neurocarrus has developed a novel biologic drug candidate, N-001, which safely disrupts peripheral pain signals by targeting actin structures within sensory neurons. This approach avoids addiction risk and does not impair motor function. The company has generated extensive preclinical efficacy and safety data but has not yet entered clinical trials. No published human clinical results as of June 2025.

Therapeutic areas: Neurology
Modalities: ProteinBiologicDrug delivery technology (novel protein-based)
Industry: Biotech

Drug pipeline

8 assets

NL-17

Preclinical

7 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Neurocarrus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurocarrus.

Explore the full profile